1. Home /
  2. Drug Approvals

Drug Approvals

Catalent to Buy Paragon Bioservices for $1.2 Billion

Catalent to Buy Paragon Bioservices for $1.2 Billion

Drugmaker Catalent reaches an agreement to buy closely held Paragon Bioservices, the latest deal in the burgeoning gene-therapy treatment space.

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.

Zogenix Shares Plummet After FDA Rejection of Seizure Treatment

Zogenix Shares Plummet After FDA Rejection of Seizure Treatment

Shares of Zogenix plunge after the FDA rejects an initial marketing application for one of its more promising epilepsy treatment drugs.

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.

Teva Pharmaceutical Initiated at Market Perform at BMO

Teva Pharmaceutical Initiated at Market Perform at BMO

Coverage of Teva Pharmaceutical is initiated at market perform at BMO with a price target of $18.

Novartis Multiple Sclerosis Drug With Price Tag of $88,000 Gets FDA Nod

Novartis Multiple Sclerosis Drug With Price Tag of $88,000 Gets FDA Nod

Mayzent tablets to treat relapsing multiple sclerosis have been approved by the FDA. But the treatment comes with a hefty price tag.

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

Jim Cramer on Why Johnson & Johnson's Anti-Depressant Is Important

Jim Cramer on Why Johnson & Johnson's Anti-Depressant Is Important

Johnson & Johnson received FDA approval for a nasal spray designed to treat patients with depression.